Cost-Effectiveness Analysis of Asciminib in Patients With Chronic Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors in Colombia.
- DOI
- 10.1016/j.vhri.2026.101691
- Published
- 2026 Sep 9
- Container
- Value in health regional issues
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vhri.2026.101691,
title = {Cost-Effectiveness Analysis of Asciminib in Patients With Chronic Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors in Colombia.},
author = {Ceballos M and Abello V and Lasalvia P and Jaramillo P and Ospina JA and Prieto N and Arias S},
year = {2026},
journal = {Value in health regional issues},
doi = {10.1016/j.vhri.2026.101691},
url = {https://doi.org/10.1016/j.vhri.2026.101691}
}RIS
TY - JOUR TI - Cost-Effectiveness Analysis of Asciminib in Patients With Chronic Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors in Colombia. AU - Ceballos M AU - Abello V AU - Lasalvia P AU - Jaramillo P AU - Ospina JA AU - Prieto N AU - Arias S PY - 2026 JO - Value in health regional issues DO - 10.1016/j.vhri.2026.101691 UR - https://doi.org/10.1016/j.vhri.2026.101691 ER -
APA
M, C., V, A., P, L., P, J., JA, O., N, P., & S, A. (2026). Cost-Effectiveness Analysis of Asciminib in Patients With Chronic Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors in Colombia.. Value in health regional issues. https://doi.org/10.1016/j.vhri.2026.101691
Source records
- pubmed · retrieved 2026-09-25T15:22:03.019Z
- europe-pmc · retrieved 2026-09-25T15:22:03.049Z